Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 58

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 1B
Chunk 58
---
 Diagnostics, Inc.2,019,231 — — — Epica International, Inc. TBD — — — Eton Pharmaceuticals, Inc. Tranche 151,239 5.86 424 327 Eton Pharmaceuticals, Inc. Tranche 218,141 6.62 148 111 Eton Pharmaceuticals, Inc. Tranche 3289,736 5.32 3,008 1,936 EyePoint Pharmaceuticals, Inc.40,910 11.00 — 127 EyePoint Pharmaceuticals, Inc.7,773 19.30 — 22 Shield Warrant (10)8,910,540 0.14 201 (193)MedMinder, System, Inc. Tranche 157,859 10.37 — — MedMinder Systems, Inc. Tranche 214,465 10.37 — — Neolight, LLC52,524 7.62 — — MolecuLight, Inc. TBD — — — 

23

AssetsRevenue RecognizedTotal gross finance receivables$289,009 $40,787 Total marketable investments580 — Fair value of warrant assets4,366 — Total $293,955 $40,787 

(1)US royalty was paid off during the year ended December 31, 2021. SWK continues to receive insignificant royalties on international sales.(2)Investment considered partially impaired.(3)Investment on non-accrual.(4)Carrying value was paid off during the year ended December 31, 2023. SWK continues to receive royalties on actual sales.(5)Flowonix Medical assets were sold to a medical device company during the year ended December 31, 2023. In exchange for releasing its lien, SWK received cash at close and is expected to receive royalties on sales of two products. The finance receivable is now classified as a royalty.(6)In July 2023, Ideal Implant assets were sold to an aesthetics company, which is expected to pay SWK a mid-single digit, capped royalty on implant sales.(7)The Veru royalty was repaid during the year ended 2024.(8)AOTI warrants exercised and converted to shares.(9)Investment paid off during the year ended December 31,